Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.

GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.

This review article discusses the aesthetic impacts of GLP-1 medications like Ozempic (semaglutide), including "Ozempic Face," skin sagging, and loss of lean mass, and explores potential recovery methods such as biostimulators, HIFU, endolaser, and PRP.

This study found that hair shedding occurs in seven out of ten users of GLP-1 receptor agonists in real-world settings, a much higher prevalence than in clinical trials, which affects treatment adherence, especially among women experiencing significant weight loss.

This research highlights the lack of clinical evidence linking GLP-1 agonists, commonly used in treating type 2 diabetes and obesity, to hair loss, despite theoretical concerns regarding potential hair health impacts.

This study suggests that among GLP-1 agonists, liraglutide and exenatide are linked to the highest rates of gastrointestinal issues, including potentially pancreatitis-related enzyme changes noted in animal models.

This study reports that GLP-1 receptors and proglucagon are expressed in the skin of newborn mice, with GLP-1 potentially playing a role in skin development and hair follicle formation.

GLP-1 RA medications may be linked to hair loss.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This publication discusses the 2021 ESC Guidelines for the prevention of cardiovascular disease in clinical practice and reports no new results.

Tirzepatide may improve hair loss by reducing insulin resistance.

This study highlights a potential association between semaglutide, a diabetes medication, and increased reports of hair loss, with researchers calling for more rigorous clinical trials to confirm and better understand the risk.

This study reports that women with polycystic ovary syndrome, especially those with a hyperandrogenic pattern, are at a higher risk for cardiovascular disease compared to other PCOS patients, likely due to related metabolic comorbidities.

This review suggests that, among non-hormonal treatments for menstrual irregularities in adolescents with PCOS, metformin is the most effective and cost-efficient option, particularly in overweight adolescent girls.

This review discusses various weight loss treatment options for managing PCOS in women, including lifestyle changes, diet, medications, and surgery, but reports no new clinical results.

Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.

This narrative review suggests that the association between weight-loss medications and telogen effluvium is primarily due to metabolic changes from rapid weight loss, rather than a direct pharmacological effect on hair follicles.

This review explores how metabolic and psychological factors contribute to binge eating disorder in women with PCOS and highlights the need for non-punitive, comprehensive management strategies.

This review explores weight loss interventions during gestation, emphasizing incretin-based therapies' potential to enhance reproductive health and address metabolic changes for better maternal and fetal outcomes.

This review reports that lifestyle modification, including diet and exercise, is essential for managing PCOS, while pharmacological and complementary treatments address specific symptoms like menstrual irregularities and insulin resistance.

This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.

This abstract does not report specific research results but introduces a book focusing on the intersection of endocrinology and aesthetic medicine and its growing importance in contemporary clinical practice.

This review observed that semaglutide may have therapeutic benefits for skin conditions like psoriasis and hidradenitis suppurativa, but reports of adverse skin reactions exist, indicating the need for further research to understand its safety and efficacy in dermatology.

In this case study, a patient developed a rash consistent with acute generalized exanthematous pustulosis after increasing the dose of semaglutide, suggesting that the reaction was likely due to the excipient propylene glycol, highlighting the importance of ingredient analysis and multidisciplinary collaboration for patient safety.

In this study, peptide nanofiber gels RG and RJ significantly accelerated the healing of deep second-degree burn wounds in vivo, with greater wound closure rates and enhanced tissue regeneration compared to controls, attributed to increased angiogenesis and reduced systemic inflammation.

In this retrospective cohort study, researchers found that exposure to 5-alpha reductase inhibitors and spironolactone in female alopecia patients was not linked to an increased risk of developing malignant or benign gynecologic tumors when compared to minoxidil use.

This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

This case report describes significant symptom improvement and hair regrowth in a man with recalcitrant folliculitis decalvans after starting tirzepatide for weight management, suggesting a potential new therapy avenue.